Prostatic Diseases  >>  hydrocortisone  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
hydrocortisone / Generic mfg.
SWOG-E8892, NCT00002881: Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

Completed
3
US
flutamide, goserelin acetate, leuprolide acetate, suramin, therapeutic hydrocortisone, orchiectomy
Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Cancer and Leukemia Group B, Southwest Oncology Group
Prostate Cancer
04/98
 
NCT00002760: Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

Completed
3
260
US
ketoconazole, therapeutic hydrocortisone, Withdrawal of antiandrogen therapy
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Prostate Cancer
03/04
04/09
SWOG-E1899, NCT00027859: Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

Completed
3
US
docetaxel, estramustine phosphate sodium, ketoconazole, therapeutic hydrocortisone
Eastern Cooperative Oncology Group, National Cancer Institute (NCI), SWOG Cancer Research Network, Cancer and Leukemia Group B
Prostate Cancer
12/04
 
PROSTATA, NCT00705822 / 2004-003885-14: Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer

Terminated
3
54
Europe
Docetaxel + Estramustine + Hydrocortisone, Docetaxel + Prednisone
Sanofi
Prostatic Neoplasms
07/09
07/09

Download Options